Zileuton Tablet, Multilayer, Extended Release
NDC Package 64380-189-01
Package Information
Zileuton tablets is zileuton extended-release tablets are indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older.Zileuton extended-release tablets are not indicated for use in the reversal of bronchospasm in acute asthma attacks. Therapy with zileuton extended-release tablets can be continued during acute exacerbations of asthma. This formulation utilizes a tablet, multilayer, extended release delivery system. Marketed by Strides Pharma Science Limited, this product is identified by NDC 64380-189 and is authorized under FDA application ANDA212670.
Identification & Billing
- RxCUI: 730834 - zileuton 600 MG 12HR Extended Release Oral Tablet
- RxCUI: 730834 - 12 HR zileuton 600 MG Extended Release Oral Tablet
- RxCUI: 730834 - zileuton 600 MG 12 HR Extended Release Oral Tablet
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 64380 - Strides Pharma Science Limited
- 64380-189 - Zileuton
- 64380-189-01 - 120 TABLET, MULTILAYER, EXTENDED RELEASE in 1 BOTTLE
- 64380-189 - Zileuton
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 64380-189-01 identifies a specific commercial package of 120 tablet, multilayer, extended release in 1 bottle of Zileuton, a human prescription drug labeled by Strides Pharma Science Limited. This tablet, multilayer, extended release is formulated for oral use and contains zileuton as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Strides Pharma Science Limited on October 15, 2022. The current certification is valid through December 31, 2027.
How is this Strides Pharma Science Limited product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 64380018901. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 120 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.